Asset Management One Co. Ltd. Purchases 7,896 Shares of Vertex Pharmaceuticals Incorporated (VRTX)

Asset Management One Co. Ltd. lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 391,213 shares of the pharmaceutical company’s stock after buying an additional 7,896 shares during the period. Asset Management One Co. Ltd. owned about 0.15% of Vertex Pharmaceuticals worth $59,434,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. boosted its position in Vertex Pharmaceuticals by 15.4% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock valued at $127,000 after purchasing an additional 132 shares during the last quarter. FNY Partners Fund LP boosted its position in Vertex Pharmaceuticals by 900.0% during the second quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock valued at $128,000 after purchasing an additional 900 shares during the last quarter. Smithfield Trust Co. acquired a new position in Vertex Pharmaceuticals during the third quarter valued at approximately $135,000. FNY Managed Accounts LLC acquired a new position in Vertex Pharmaceuticals during the third quarter valued at approximately $162,000. Finally, Dupont Capital Management Corp acquired a new position in Vertex Pharmaceuticals during the second quarter valued at approximately $186,000. 93.33% of the stock is owned by institutional investors.

Several research analysts recently commented on the company. BMO Capital Markets reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, September 27th. Robert W. Baird reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Friday, October 27th. Needham & Company LLC reissued a “buy” rating and set a $195.00 price target on shares of Vertex Pharmaceuticals in a research report on Sunday, September 17th. Vetr cut Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 price target for the company. in a research report on Monday, September 4th. Finally, HC Wainwright reissued a “hold” rating and set a $85.00 price target on shares of Vertex Pharmaceuticals in a research report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-three have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $173.15.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at $137.28 on Thursday. The firm has a market capitalization of $34,991.63, a P/E ratio of 230.60, a PEG ratio of 3.31 and a beta of 1.58. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.14 and a current ratio of 3.28. Vertex Pharmaceuticals Incorporated has a 52 week low of $71.46 and a 52 week high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.49. The company had revenue of $578.20 million for the quarter, compared to analyst estimates of $522.07 million. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The firm’s quarterly revenue was up 39.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.16 earnings per share. research analysts expect that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current year.

In other news, COO Ian F. Smith sold 75,000 shares of the stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $145.06, for a total transaction of $10,879,500.00. Following the transaction, the chief operating officer now owns 114,188 shares in the company, valued at $16,564,111.28. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Sangeeta N. Bhatia sold 7,073 shares of the stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $143.05, for a total value of $1,011,792.65. Following the transaction, the director now owns 11,026 shares in the company, valued at approximately $1,577,269.30. The disclosure for this sale can be found here. In the last quarter, insiders have sold 218,519 shares of company stock worth $31,819,910. 1.80% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.com-unik.info/2017/12/07/asset-management-one-co-ltd-purchases-7896-shares-of-vertex-pharmaceuticals-incorporated-vrtx.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

What are top analysts saying about Vertex Pharmaceuticals Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vertex Pharmaceuticals Incorporated and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit